We focus on identifying, supporting and translating breakthrough discoveries into new medicines for rare diseases.
Our priority areas are rare neurological diseases, metabolic and developmental diseases, and childhood cancers. These areas have high unmet clinical need and align with existing expertise and infrastructure.
Our pipeline of rare disease drug development projects will be built on the addition of 10 new Oxford-Harrington Rare Disease Scholar projects every year. We source projects from across our networks to advance the most promising academic discoveries into the clinic.
Philanthropy is critical to supporting early-stage rare disease drug development projects and led to our first named priority disease: Friedreich’s Ataxia (FA). The OHC has established the FA Alliance at Oxford, a consortium committing their expertise to developing new therapies for FA.
